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| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a mortality rate that is almost the same as the morbidity rate. 1 A clinical reason for the extremely poor prognosis of PDAC is the difficulty of diagnosis in the early stages, 2 when complete remission following surgical removal is possible. 3 Invasion of PDAC into adjacent vessels or neurons 4,5 also contributes to the extremely poor prognosis of PDAC patients. In addition, patients on chemotherapeutic anti-cancer agents 6 fail to achieve complete remission and do not show a marked improvement in prognosis. Therefore, the pathology of PDAC needs to be better understood so that novel diagnostics and therapeutics that improve the prognosis can be developed.
The host immune system plays a major role in protecting the host from external invading pathogens and internal neoplasms. However, the immune system is composed of numerous mediators that have pro-or anti-cancer effects. 7 We previously reported that PDAC was associated with immune responses both in local tumor tissues and peripheral blood cells. 8 However, natural immune responses in PDAC patients are inadequate in combatting cancer. This is evidenced by the extremely poor prognosis of PDAC patients even after chemotherapy treatment, which usually fails to yield a completely curative response.
In this study, we established intraperitoneal-dissemination and liver-metastasis PDAC mouse models. We observed Gr-1-positive myeloid cells in local PDAC tissue and peripheral blood. In intraperitoneal-dissemination and liver-metastasis murine models 
| MATERIAL S AND ME THODS

| Cell line
The PDAC cell line, PAN02 (NCI-Frederick, Frederick, MD, USA), was cultured and expanded in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 μg/mL penicillin and streptomycin (P/S; Life Technologies). The cells were cultured at 37°C in an incubator with 5% CO 2 . Franklin Lakes, NJ, USA) was injected intraperitoneally. To determine the effect on survival, anti-Gr-1 was administered twice a week for up to 5 weeks in the intraperitoneal-dissemination PDAC models, and for up to 8 weeks in the liver-metastasis PDAC models. The experimental plan for the use of mice was approved by our institutional review board.
| Murine PDAC models and treatments
| Isolation of TICs
Pancreatic ductal adenocarcinoma tissue samples were obtained and cut into small pieces using scissors, placed in 100 μL PBS containing heparin sodium (1000 U/mL; Mochida, Tokyo, Japan), homogenized, and digested with 300 U/mL collagenase Type I and 2000 U/mL DNase I (Sigma-Aldrich) in PBS in gentleMACS™ C Tubes, using a gentleMACS™ Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). Then, the dissociated cells were collected by centrifugation. The cells were treated with ACK Lysing Buffer (Life Technologies) to lyse erythrocytes.
The cell suspension was sequentially filtered through 100 and 40-μm cell strainers (BD Biosciences) and then centrifuged. The cells were suspended in 5 mL 40% Percoll™ PLUS (GE Healthcare, Uppsala, Sweden), which was then gently transferred over 3 mL Histopaque ® -1083
(Sigma-Aldrich). The tube was then centrifuged to collect inflammatory cells in the layer between the Percoll™ and Histopaque ® layers.
treatment was associated with an immune response consistent with an anti-cancer effect, and depletion of myeloid-lineage cells played an important role in enhancing anti-cancer immunity associated with GEM treatment.
K E Y W O R D S
anti-cancer immunity, chemotherapy, Gr-1, myeloid-lineage cells, pancreatic cancer
| Isolation of white blood cells (WBCs)
To isolate WBCs, withdrawn blood from mice under anesthesia was transferred to a heparin sodium vacutainer (Venoject II, VP-H100K;
Terumo, Tokyo, Japan) pre-filled with PBS. The cell suspension was filtered through a 40-μm strainer and centrifuged. The pellet was resuspended in ACK buffer to lyse the red blood cells and then culture medium was added to neutralize the buffer. After centrifugation, the cells were collected and used for the experiments.
| Flow cytometry
Isolated WBCs and TICs from mice were suspended in PBS supplemented with 2% bovine serum albumin (Sigma-Aldrich 
| Quantitative real-time PCR (qRT-PCR)
The qRT-PCR was performed as previously described 9 with modifications: the reaction was conducted with the cDNA mixed with 
| Apoptosis detection assay
| Caspase-3 activity assay
Caspase-3 activity was assessed using a colorimetric CaspACE™
Assay System (Promega, Madison, WI, USA) in accordance with the manufacturer's protocol. Briefly, PAN02 cells were cultured in culture media with 300 μg/mL GEM and either the pan-caspase inhibitor Z-VAD-FMK (Promega) or PBS (negative control) for 16 hours.
After harvesting, centrifuging and washing the cells with PBS, the cells obtained were lysed. The lysates were incubated with labeled
Asp-Glu-Val-Asp-p-nitroanilide (DEVD-pNA) substrate, and then absorbance at a wavelength of 405 nm was measured.
| Arginase assay
White blood cells from PDAC mice and control mice were stained with FITC-conjugated anti-CD11b and PE-conjugated anti-Gr-1 antibodies and then analyzed with a FACS ARIA II ® cytometer (BD Biosciences) to sort CD11b+Gr-1+ cells. The collected cells were used for colorimetric quantification of arginase activity using a QuantiChrom™ Arginase Assay Kit (BioAssay Systems, Hayward, CA, USA) as per the manufacturer's protocol. Briefly, the cells were lysed and centrifuged, and the collected supernatants were incubated with a chromogen that forms a colored complex with urea.
The emitted color was read at an optical density of 430 nm using a Tecan Sunrise™ microplate reader (Tecan Group Ltd., Männedorf, Switzerland) and the arginase activity of each sample was calculated.
| Immunohistochemical analysis
Immunohistochemistry was performed as described previously, 
| Statistical analysis
IBM SPSS Statistics (IBM Corp., Armonk, NY, USA) was used for statistical analyses. The Kaplan-Meier estimator was used to measure the fraction of survival in mice, and the log-rank test was then performed to compare the survival distributions. The Mann-Whitney U test was used to compare the data from the IFN-γ secretion assay; the Student's t-test was used for the Arginase assay. Statistical significance was determined to be P < 0.05.
| RE SULTS
| Murine PDAC models and immune responses
We established murine intraperitoneal-dissemination PDAC models and murine liver-metastasis PDAC models by intraperitoneal injection of PAN02 cells and subcapsule insertion in the spleen under laparotomy, respectively (Figure 1 ). In the intraperitoneal-dissemination PDAC mice, relatively small tumor nodules were disseminated in the 
| GEM treatment and associated anti-cancer immune response in murine PDAC models
We next assessed whether the chemotherapeutic reagent for PDAC treatment, GEM, had therapeutic efficacy for treating murine pancreatic cancer. We confirmed that GEM treatment induced exposure of annexin V on the plasma membrane of PAN02 pancreatic cancer cells in vitro (Figure 2A ). We also observed that caspase-3 activity was higher in PAN02 cells treated with GEM than in nontreated cells ( Figure 2B ), implying that GEM is directly cytocidal to PAN02 cells. Next, we found that GEM treatment significantly prolonged the survival of intraperitoneal-dissemination PDAC mice and liver-metastasis PDAC mice compared to untreated mice in vivo ( Figure 2C ). Thus, GEM treatment was therapeutically beneficial for treating murine pancreatic cancer.
We next assessed how GEM affected PDAC-associated immune responses. We observed that CD11b+Gr-1+ myeloid cell numbers were higher in the peripheral blood of intraperitoneal-dissemination and liver-metastasis PDAC mice than in wild-type mice without tumors ( Figure 3 ). We also found that the CD11b+Gr-1+ cells isolated from peripheral blood of intraperitoneal-dissemination PDAC mice had high arginase activity compared to that of wild-type mice We also assessed the function of CD8+ cells isolated from peripheral blood and from tumor tissue of PDAC mice treated with GEM.
We observed that the number of IFN-γ-secreting CD8+ TICs was increased in PDAC mice treated with GEM ( Figure 4E ). Furthermore, a The cleaving activity was determined by colorimetric assay; the Student's t-test was performed to obtain the Pvalue. C, Cumulative survival curves of intraperitoneal-dissemination and liver-metastasis PDAC mice (n = 6) involving twice a week injection of GEM. PBS was injected in the control group that received no treatment. The log-rank test was performed to obtain the P-value and IV collagen compared to that in untreated mice ( Figure S4 ).
| Anti-Gr-1 antibody treatment augmented the therapeutic effect of GEM in PDAC murine models
The above data imply that myeloid lineage cells in peripheral blood, as well as tumor tissues in PDAC murine models, are associated with tumor formation, and that GEM treatment decreases the proportion of myeloid cells in peripheral blood and tumor tissues. We next assessed whether further depletion of myeloid cells using an anti-Gr-1 antibody in combination with GEM treatment would augment the anti-cancer effect. We observed that GEM treatment and anti-Gr-1
antibody treatment significantly prolonged survival in intraperitonealdissemination PDAC mice which underwent GEM treatment twice a week ( Figure 5A ). When we administered GEM into the livermetastasis PDAC mice weekly, not twice a week, survival prolongation effect by GEM treatment alone was not obvious. However, when we administered GEM weekly together with anti-Gr-1 antibody treatment, we also observed this combined treatment relatively prolonged survival in liver-metastasis PDAC mice that received GEM weekly ( Figure 5B ). In both intraperitoneal-disseminated and liver-metastasis PDAC mice treated with a combination of anti-Gr-1 antibody therapy and GEM, the proportion of CD11b+Gr-1+ myeloid cells in peripheral blood was even lower than in peripheral blood isolated from mice that 
| D ISCUSS I ON
In this study, we used murine intraperitoneal-dissemination and liver-metastasis PDAC models to analyze both natural host immune were also affected by GEM treatment. Specifically, there was a decrease in the numbers of Gr-1+ infiltrating inflammatory cells, and an F I G U R E 6 DNA microarray analysis of whole peripheral blood cells from liver-metastasis pancreatic ductal adenocarcinoma (PDAC) mice following treatment. Liver-metastasis PDAC mice underwent the following treatments on day 36: gemcitabine (GEM) in combination with anti-Gr-1 antibody (n = 3), GEM (n = 3), and no treatment (n = 3). Two days later, total peripheral blood was withdrawn and total RNA was isolated for cDNA microarray analysis. A, Dendrogram for post-analysis sample clustering (27 144 genes which passed filter). B, Gene set class comparison analysis of biological processes related to neutrophils and anti-cancer cytotoxic immune responses that passed the LS/KS permutation test or the Efron-Tibshirani's test with significance threshold (P < 0.005) increase in the numbers of T cells with an enhanced cytotoxic CD8+
T cell response. Anti-Gr-1 antibody treatment in combination with GEM prolonged the survival of PDAC mice. The gene-expression profile of peripheral blood cells showed that anti-cancer immune responses were prominent in PDAC mice treated with GEM and antiGr-1 antibody.
Cancer-associated inflammation has been intensively investigated. Such inflammation has an important role in disease progression/regression, and its effect on prognoses has been studied in various cancers. 12, 13 Inflammatory cells consist of various subtypes and lineages, including myeloid and lymphoid cells. [14] [15] [16] Consistent with the importance of inflammatory cells in cancer, the findings of the current study suggest that myeloid cells are cancer-prone immune-mediating cells that are found in both peripheral blood and TICs. The population of myeloid-lineage cells originating from bone marrow is highly heterogeneous, 17 and it has been proven that immune-suppressive myeloid cells play an important role in inhibiting anti-cancer immunity. 18 Thus, further detailed investigations of myeloid-lineage cells should be performed to understand their role in the context of PDAC tumor development.
A major goal of the current study was to examine chemotherapyassociated alterations in host immune responses to tumor-associated inflammation. GEM is a deoxycytidine nucleoside analog, 19 and an anti-metabolite that is cytotoxic to cancer cells. 20 It would be of value to discover a chemotherapeutic agent with a mechanism of action that has a direct cytocidal effect on cancer cells and also influences host inflammatory responses to cancer tissues. 21 In our intraperitoneal-dissemination and liver-metastasis PDAC mice models, GEM treatment decreased numbers of myeloid cells and increased CD4+ and CD8+ cells. In other cancer mice model, GEM was proven to be suppressive to myeloid-lineage cells, especially, myeloid-derived suppressor cells. 22 Additionally, in BALB/c mice system, GEM depleted B-lymphocytes; in contrast, tumor-specific CD4+ and CD8+ cells were augmented. 23 Our current findings of immunomodulatory effects by GEM in C57BL/6J PDAC mice models are consistent with these previous reports. Detailed relations of myeloid-lineage suppression and augmentation of CD4+ and CD8+ cells by GEM treatment remains to be disclosed; however, decrease of suppressor cells in myeloid-lineage cells is considered to be a mechanism since they inhibit tumor-reactive T cell response, 24 by production of arginase, inducible NO synthase, etc. 25 Thus, gemcitabine's therapeutic effect is not only dependent on DNA synthesis halt, but also on immune-modulation with anti-cancer effects.
Despite of these intriguing findings, cancer tissues affected by chemotherapeutic agents should be further investigated, since further complex host immune responses are involved 26 as a consequence of anti-cancer chemotherapeutic agents' effects on cancer tissues.
Novel anti-cancer immune therapies such as those that target immune checkpoints 27 have emerged as treatments for cancers including melanoma 28 and renal cell carcinoma. 29 As for PDAC, there have been no reports of effective immune therapies in clinical trials. 30 The findings in the current study show that immune modulation induction of anti-cancer immunity by depletion of myeloid-lineage cells is a promising novel strategy for treating PDAC when used in combination with chemotherapy. However, the prolongation effect of survival by anti-Gr-1 antibody treatment combined with GEM was limited, especially in liver metastasis PDAC models. PD-1 and PD-L1 expressing cells were significantly induced in tumor tissues of both intraperitonealdissemination and liver-metastasis murine PDAC models, when they were treated with GEM. Therefore, targeting these immune checkpoints molecules together with depletion of myeloid-lineage cells might be novel approach for PDAC immune-chemotherapy.
In conclusion, immune responses in murine PDAC models were affected by GEM chemotherapy. Moreover, the induced anti-cancer 
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